Introduction {#Sec1}
============

Schizophrenia (SCZ) is a severe mental disorder affecting \~1% of the population and is characterized by the presence of psychosis and other features, such as negative (i.e., flattened affect and social withdrawal) and disorganization symptoms (e.g., disorganized speech and behaviour). Symptomatic and psychosocial deterioration progress rapidly during the period just after the onset of the disorder, termed the first episode of psychosis (FEP)^[@CR1]^. Moreover, reports indicate that brain abnormalities and cognitive deficits are already present in the FEP^[@CR1]^, even though patients are not affected yet long exposure to antipsychotics^[@CR2],[@CR3]^.

SCZ is highly heritable (\~80%)^[@CR4]^. The most recent Genome-Wide Association Study (GWAS) for SCZ in the Psychiatric Genomics Consortium (PGC) wave 2 (PGC2) tested the association of millions of single-nucleotide polymorphisms (SNPs) and other types of genetic variations in \~34,000 cases and \~113,000 controls, and was particularly successful in uncovering new genes and pathways for the disorder^[@CR5]^. For SCZ (and other psychiatric disorders), it is now well accepted that, while no single variant accounts for a large proportion of cases, thousands of genetic variants act together to confer the majority of the genetic risk for the disorder---a polygenic architecture of risk^[@CR6],[@CR7]^.

Purcell et al.^[@CR8]^ developed and applied the method proposed by Wray et al.^[@CR7]^ to calculate a polygenic risk score (PRS) explaining 2--3% of variance in SCZ case-control status^[@CR7],[@CR8]^. With the large increases in sample size enabled by international GWAS consortia, the SCZ PRS has become more powerful. Using the PGC2 SCZ GWAS as a training sample^[@CR5]^, predictive SNPs achieving a nominal *p*-value threshold can be selected and the PRS of an individual in independent sample can be calculated. More specifically, the effect size estimated in the training sample for each SNP's risk allele is multiplied by the number of risk alleles present in an individual. This is then summed across all variants selected in the genome to yield a PRS for every individual in a training sample^[@CR8],[@CR9]^.

Such a PRS has a much larger effect size than any single genetic variant and does not need a large sample size for the target sample as long as it is estimated from a very large training sample^[@CR9]^. The SCZ PRS represents a genetic estimate of liability to the disorder and is a normally distributed quantitative trait that can be applied in many ways. For SCZ, the PRS has been correlated with quantitative variables, such as severity of symptoms^[@CR10]^ and prefrontal activity^[@CR11]^. For bipolar disorder, PRS has been correlated to function and brain structures in individuals at risk^[@CR12],[@CR13]^, and, for depression, it has been correlated with the reduction of the cortical volume in specific regions^[@CR14]^. A recent paper by Vassos et al.^[@CR15]^ reported that SCZ PRS is associated with diagnosis inFEP patients. One recent study reported a positive correlation between SCZ PRS and negative symptoms in an (unaffected) adolescent population cohort^[@CR16]^. Recently, another article found positive associations between a genetic (rather than polygenic) risk score generated with 84 SNPs with positive and negative symptoms at the FEP, but not after treatment^[@CR17]^.

No study, to our knowledge, has examined the correlation of PRS with the untreated symptom profile of SCZ patients or the response to treatment in FEP patients. In this study, we test if the SCZ PRS is correlated with symptomatology, severity and response to antipsychotics during FEP in a serial longitudinal sample of initially treatment naive patients.

Methods {#Sec2}
=======

Recruitment and consent {#Sec3}
-----------------------

We enrolled patients with FEP at admission to the Centro de Atenção Integral a Saúde Mental (CAISM), São Paulo. The study protocol was designed to address the acute but temporary lack of capacity in FEP patients at admission. When a patient was admitted meeting the inclusion criteria (below), medical staff explained the study to family members, provided printed information sheets and, if agreeing, families then signed a written informed consultee consent with the assent of the patient. At the follow-up assessment, the patients were directly consented into the study, provided they had capacity. If subjects lacked capacity at the follow-up assessment, consent was taken at a later stage when capacity was regained. The local Research Ethics Committee of Universidade Federal de São Paulo (CEP-UNIFESP 0603/10) and the national Brazilian Ethics Committee (CONEP-CAAE 33148114.6.0000.5505, CAAE 48242015.9.0000.5505) approved the research protocol.

Longitudinal cohort of FEP patients {#Sec4}
-----------------------------------

Our cohort of antipsychotic-naiveFEP patients includes 154 subjects recruited from a psychiatric emergency unit in São Paulo (Brazil). The diagnosis of a psychotic disorder was established by trained psychiatrists using Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) criteria, using the Structured Clinical Interview for DSM-IV (SCID-I). Inclusion criteria were aged between 16 and 40 years without previous history of antipsychotic medication and with confirmed non-affective psychosis (SCZ, schizophreniform disorder or brief psychosis disorder diagnosis) after two months of treatment. Prior or current treatment with benzodiazepines was allowed. Patients with psychotic episodes due to a general medical condition, substance-induced psychotic disorder, intellectual disability, major depressive disorder or bipolar disorder were excluded.

A total of 60 patients met criteria for antipsychotic-naive FEP after the follow-up (FEP, *N* = 60). These patients were assessed at baseline and followed up for 9.03 ± 2.76 weeks of risperidone treatment. Four patients were taking benzodiazepines and one clonazepam, at baseline. During follow-up, besides risperidone, 12 were taking clonazepam and 7 mood stabilizers.

The healthy control group (*N* *=* 60) comprised age-gender-and-ethnicity-matched volunteers with no first-degree family history of psychotic disorders, who were evaluated by trained psychiatrists using a modified SCID-I to ensure no current or previous psychiatric diagnoses. Peripheral blood samples were collected in EDTA tubes at baseline and follow-up for patients and after psychiatric interview for controls.

Clinical assessments {#Sec5}
--------------------

All psychiatrists had the same training at the "*Programa de Esquizofrenia da UNIFESP*" and the FEP patients were always assessed by the same psychiatrist at both time points for the following scales: (a) PANSS (Positive and Negative Syndrome Scale), (b) CGI (Clinical Global Impression Scale)^[@CR18]^, (c) GAF (Global Assessment of Functioning Scale), (d) CDSS (Calgary Depression Scale for SCZ)^[@CR19]^.

Symptom clusters (negative, positive, disorganization, excited and anxiety/depression) from the PANSS items^[@CR20]^ were calculated using the algorithm from a previous study in a Brazilian population^[@CR21]^. For more information about each symptom cluster, see Supplementary Table [S1](#MOESM1){ref-type="media"}. Response to treatment was defined as a \> 50% reduction in baseline PANSS total score^[@CR22]^. GAF is the only scale where higher values represent less impairment; thus we transformed to them to negative values (referred to as −GAF).

DNA isolation {#Sec6}
-------------

Whole blood was collected into EDTA tubes, and genomic DNA isolation was performed using the Gentra Puregene Kit (Qiagen) according to the manufacturer's protocol.

Genomic arrays {#Sec7}
--------------

The genotyping was performed at King's College London using the Infinium PsychArray-24 BeadChip (Illumina) with a GWAS core backbone (\~590 K markers) and specific content from the Psychiatric Genomics Consortium: <https://www.med.unc.edu/pgc/psychchip>.

Quality control and imputation {#Sec8}
------------------------------

For the quality control (QC) parameters, we removed SNPs with a minor allele frequency (MAF) \< 1%, *Locus* missingness \> 10% or Hardy--Weinberg disequilibrium significance \< 0.00001. We also excluded individuals with missingness \> 10% and an estimation of identity-by-descent \> 0.12. Genotype imputation was performed using the <https://imputation.sanger.ac.uk> using as Reference Panel the Haplotype Reference Consortium (release 1) with 32,488 samples (39 M sites) and the Pre-phasing algorithm SHAPEIT2. After post-imputation QC, using the same parameters as above, \~ 9 M SNPs were analysed.

Polygenic risk scores {#Sec9}
---------------------

For more information about how the scores are calculated, please see the Supplementary Material of Purcell et al.^[@CR8]^. To generate the PRS we used the PRSice software ([www.PRSice.info](http://www.PRSice.info)) default options. The SCZ sample from PGC2 (downloaded from <https://www.med.unc.edu/pgc>) was used as the training sample and our imputed genotyping sample as the target. The PGC2 SCZ PRS is generated from many individual samples that may represent more chronic and severe SCZ, such as patients on clozapine. This means the PGC PRS represents a powerful tool to understand the influence of SCZ risk on clinically important symptom dimensions pre-treatment. We performed *P*-value-informed clumping with a cutoff of *r*^2^ = 0.1 using a 250-kb window and calculated scores per individual for multiple *p*-threshold (ranging from 0.0001 to 0.5 with increments of 0.00005) including or excluding the MHC (major histocompatibility complex) region on chromosome 6, which has a complex linkage disequilibrium structure. Given that our sample is sampled from an admixed south eastern Brazilian population, we carefully assessed population stratification and used the first four components generated by plink1.9 software were used as covariables. Posteriorly, PRSice runs a regression to find the best *p*-threshold based on the explained variance (Nagelkerke's pseudo-*r*^2^ correlation) and in our case gave PRSs based on the most FEP case-control variance explained.

Statistical analysis {#Sec10}
--------------------

We used R for all statistical analysis. With the PRSs calculated for the case-control comparison, we used a generalized linear model to test PRS associations assuming a Poisson distribution (Poisson regression), which is more suitable for ordinal variables (such as psychiatric scales), using clinical traits as the dependent variable and the best *p*-threshold PRS with the first four principal components as the independent variables and covariates. As clinical outcome variables, we considered, for both time points, GAF score, total CGI score, total PANSS scores and the five PANSS dimension clusters suggested by Wallwork et al.^[@CR20]^ and validated by Higuchi et al.^[@CR21]^ in the Brazilian population. GAF values were transformed to negative values (−GAF), so all clinical variables were easily compared, with high values meaning high symptomatology. We defined as outliers those observations lying beyond 1.5 times the 'Inter Quartile Range' - the difference between 75th and 25th quartiles.

We applied the Bonferroni correction for multiple comparisons (number of psychiatric scales tested *N* = 36), considering as significant a *p*-value \< 0.0014 (0.05/36). As the Brazilian population is known to be a highly admixture population, we first plotted case and controls principal components to check if they have similar background and then we did a sensitivity analysis considering only full European ancestry cases.

Using the residuals from the PRS with principal components, we tested if the available demographics could be potential confounders. Further, we tested if response to risperidone overall or within subtypes of FEP included in our study (SCZ or schizophreniform) was associated with SCZ PRS. First, we tested the change in symptoms from baseline to the follow-up and if the subtype of FEP was associated with the PRS using a Poisson regression. Second, we tested the correlation between the change in total PANSS and PRS using a Pearson correlation. Finally, we verified if there was an association of clonazepam or mood stabilizers with CDSS, CGI, GAF and PANSS symptoms that could be affecting the results.

Results {#Sec11}
=======

Table [1](#Tab1){ref-type="table"} shows the clinical and demographic characteristics of the participants. Smoking rates significantly higher in cases than in controls. Patients showed improvement after nine weeks of risperidone treatment for all scales and symptom clusters, except for PANSS negative. Figure [S8](#MOESM1){ref-type="media"} shows a heatmap of the correlations among the tested clinical variables, demonstrating, a high correlation between PANSS depressive factor and CDSS, and between GAF and most clinical variables. Table [S2](#MOESM1){ref-type="media"} and [S3](#MOESM1){ref-type="media"} shows that there are no associations between demographics with either PRS or clinical variables.Table 1Clinical and demographic characteristics of the participants in this studyVariableHealthy controls (*N*=59)Antipsychotic-naive FEP (*N*=60)FEP after treatment (*N*=60)*p*-valueGender (%)M:34 (57.6%)M:40 (66.7%)0.309Age in years; mean (SD)25.97 (7.48)25.63 (7.46)0.808Currently smoking (%)*N* = 2 (3.6%)*N* = 12 (23.5%)0.002Family history of psychosis (%)*N* = 23 (50%)Cannabis use (%)*N* = 18 (52.9%)Other drugs use (%)\**N* = 13 (41.9%)Family income in US\$/month (SD)870.59 (792.31)BMI in kg/m^2^23.58 (3.78)PANSS negative; mean (SD)27.37 (10.51)25.02 (9.28)0.127PANSS disorganization/cognition; mean (SD)26.96 (8.58)19.91 (6.22)5.029 × 10^-8^PANSS excitement; mean (SD)24.69 (9.09)13.22 (5.62)7.84 × 10^-14^PANSS positive; mean (SD)34.75 (7.32)21.23 (9.52)2.46 × 10^-13^PANSS depression/anxiety; mean (SD)24.24 (8.79)18.11 (7.85)2.97 × 10^-5^PANSS total94.55 (20.94)68.21 (20.31)1.71 × 10^-10^GAF; mean (SD)31.21 (10.52)55.47 (16.61)1.34 × 10^-11^CGI; mean (SD)4.83 (0.72)3.35 (1.26)1.77 × 10^−11^CDSS; mean (SD)4.64 (5.04)2.48 (4.27)0.007*M* male, *SD* standard deviation, *FEP* first-episode psychosis, *PANSS* Positive and Negative Syndrome Scale, *CGI* Clinical Global Impression Scale, *GAF* Global Assessment of Functioning Scale, *CDSS* Calgary Depression Scale for Schizophrenia\*Drugs including cocaine, sedatives, stimulants, hallucinogens, opioids and gases

Brazilian admixture sample {#Sec12}
--------------------------

Cases and controls showed similar principal components structure, and when analysing only the European ancestry individuals (self-declared and consistent with the genetic estimates) the direction and magnitude of associations remained the same (Table [S5](#MOESM1){ref-type="media"} and Figures [S1](#MOESM1){ref-type="media"}, [S7](#MOESM1){ref-type="media"}).

Polygenic risk {#Sec13}
--------------

The number of independent SNPs analysed for each threshold and cohort is described in Supplementary Table [S4](#MOESM1){ref-type="media"}. With or without the MHC region, results were similar; thus, we carried on including the MHC region to increase the number of analysed SNPs and, consequently, the power of our analysis. The PRS was significantly different between cases and controls (Fig. [1](#Fig1){ref-type="fig"}) with a best *p*-threshold of 0.0112 (*N*~SNPs~ = 21,622) and an explained variance of 0.19 (Nagelkerk's pseudo-*r*^2^). Figure [S7](#MOESM1){ref-type="media"} shows the normal distribution of the PRS for cases and controls, and Figure [S10](#MOESM1){ref-type="media"} shows the odds ratio (OR) of psychosis for quantiles of PRS.Fig. 1Graph from PRSice showing the explained variance (*y*-axis) for each *p*-threshold (*x*-axis) to identify cases and controls for our sample

PRS and clinical variables relation {#Sec14}
-----------------------------------

At baseline (antipsychotic naive FEP), we find a positive association PRS with the PANSS excitement factor (five-factor model) (*B* = 566.7; *p*-value = 0.0003) and a trend for association with --GAF (*B* = 436.1; *p*-value = 0.003). PRS showed a positively trend for depressive symptoms at baseline (CDSS total: *B* = 1042.3; *p*-value = 0.0039) but became significantly negatively associated with depressive symptoms after risperidone treatment (CDSS total: *B* = −1800.2; *p*-value = 0.0004). The results are summarized in Table [2](#Tab2){ref-type="table"} and Figures [S2](#MOESM1){ref-type="media"}--[S4](#MOESM1){ref-type="media"}.Table 2PRS correlation with clinical variable during the baseline and the follow-upTimeClinical variable*N*B*p*-valueBaseline (antipsychotic naive FEP)CGI5072.80.8436^a^−GAF48436.10.0030^a^CDSS total511042.30.0039PANSS total5338.10.6390^a^PANSS positive53400.00.0278PANSS negative53−205.60.3048PANSS general psychopathology53−20.20.8886Five-factor model^[@CR21]^PANSS negative53−168.20.2655PANSS disorganization/cognition53−32.90.8281^b^PANSS excitement53566.70.0003PANSS positive5327.10.8382PANSS depression/anxiety53−112.80.4761Follow-up (9 weeks treated with risperidone)CGI51−137.40.7588−GAF53−132.80.2281^b^CDSS total53−1800.20.0004PANSS total54−113.40.2215PANSS positive56277.30.3141PANSS negative56−358.30.0894PANSS general psychopathology54−287.90.1140Five-factor model^[@CR21]^PANSS negative56−180.60.2329PANSS disorganization/cognition56−75.80.6608PANSS excitement56216.40.3048PANSS positive5610.00.9522^b^PANSS depression/anxiety55−575.00.0013*PANSS* Positive and Negative Syndrome Scale, *CGI* Clinical Global Impression Scale, *GAF* Global Assessment of Functioning Scale, *CDSS* Calgary Depression Scale for Schizophrenia^a^Significant *p*-values without Bonferroni correction^b^Significant *p*-values with Bonferroni correction

Looking at response to risperidone, we analysed the five PANSS factors and other scales, we observed a positive association for ΔCDSS (*B* = 717; *p*-value = 0.0006) (Table [3](#Tab3){ref-type="table"}). However, considering the total PANSS, there was no correlation between Δtotal PANSS and PRS (*t* = 0;62633, df = 49; *p*-value = 0.534; *r* = 0.089). Although a borderline association was observed between PANSS-excitement at the follow-up and mood stabilizer use (*N* = 7), the relationship between PRS and PANSS-excitement remained not significant even adding this as a covariate (*B* = −110, *p* = 0.94).Table 3PRS association with clinical variables of risperidone treatment responseClinical variables (follow-up - baseline)*N*B*p*-valueFive-factor model^[@CR21]^ΔPANSS negative53−71.60.5948ΔPANSS positive53−74.50.6824ΔPANSS disorganization53−35.30.8493ΔPANSS depression/anxiety52222.70.1173^a^ΔPANSS excitement53473.50.0034^b^ΔCDSS49717.20.0006Delta was calculated subtracting the measures of follow-up minus the baseline^a^Significant *p*-values without Bonferroni correction^b^Significant *p*-values with Bonferroni correction

Within FEP subtypes, depressive symptoms (CDSS) were positively associated with PRS in both FEP subtypes when analysed separately at baseline (B~schizophrenia~ = 1746.1; p~schizophrenia~ = 0.002; B~schizophreniform = ~2660.0; p~schizophreniform = ~0.036), while PANSS excitement and −GAF was associated only in the schizophreniform subgroup (*B* = 1393.3; *p* = 9 × 10^-5^ and *B* = −1449.1; *p* = 1.3 × 10^-4^, respectively) (Table [4](#Tab4){ref-type="table"}, Supplementary Figs S5 and S6).Table 4Association between the statistically significant clinical variables with PRS splitting the FEP patients into FEP subtypes according to the follow-up diagnosisSubtypeClinical variableTimepoint*N*B*p*-valueSchizophreniform^a^−GAFBaseline9−1449.10.00013^b^CDSSBaseline92660.00.03594CDSSFollow-up10−2323.70.20033^a^PANSS excitementBaseline111393.30.00009PANSS depression/anxietyFollow-up10−622.30.15126^b^ΔPANSS excitementBaseline - follow-up11877.80.02002ΔCDSSBaseline - follow-up9497.40.30954Schizophrenia only−GAFBaseline27300.30.21538^b^CDSSBaseline291746.10.00217^a^CDSSFollow-up27−3739.30.00009PANSS excitementBaseline29206.50.39645^a^PANSS depression/anxietyFollow-up29−1286.20.00002ΔPANSS excitementBaseline - follow-up29324.90.19858^a^ΔCDSSBaseline - follow-up271358.70.00002^a^Significant *p*-values with Bonferroni correction^b^Significant *p*-values without Bonferroni correction

Given the different pattern of association between depressive symptoms (CDSS) and PRS at the baseline (positive association) and after treatment (negative association), we generated a trajectory plot to visualize each individual symptom in both time points (Figure [S9](#MOESM1){ref-type="media"}). We can note that those individuals with high PRS tend to show a decrease in their depressive symptoms after risperidone treatment, while those with low PRS tend to maintain or increase their level of depressive symptoms.

Discussion {#Sec15}
==========

In this study, we demonstrate for the first time that the SCZ PRS is associated with different clinical symptoms during the pre-treatment stage of FEP. Although recently Sengupta et al.^[@CR17]^ reported positive associations between PRS and clinical variables and FEP, it is important to note that our methods were different in many aspects; we included (1) only non-affective FEP, (2) only antipsychotic naive FEP, (3) applied a standardized treatment (risperidone) and (4) calculated the PRS using more than 21 K SNPs (compared with 84 used by them). Specifically, in pre-treatment FEP patients, we identified a positive correlation of PRS with depressive symptoms (CDSS total), excitement symptoms (PANSS-excitement factor) and with Global Assessment of Functioning (−GAF). After standardized treatment for 9 weeks with risperidone, we observed no positive association for these or other clinical measurements, but a negative correlation with PRS emerges for both CDSS and PANSS depressive/anxiety factor. Concordant with this, Sengupta et al.^[@CR17]^ observed similar results for CDSS, although not reaching statistical significance, probably because of the lower power of including only 84 SNPs in the genetic risk score. These results suggest the potential aetiological importance of depression (and anxiety) in SCZ. In sensitivity analyses, we found that observed baseline positive correlation with PANSS excitement and --GAF was driven by the subgroup composed by individuals with schizophreniform or brief psychosis disorder diagnoses (Table [4](#Tab4){ref-type="table"}), while the positive correlation of SCZ PRS with depressive symptoms was present irrespective of diagnostic group.

Looking at treatment response, we found that pre-treatment baseline to post-treatment follow-up changes for PANSS excitement (ΔPANSS excitement**)** and CDSS (ΔCDSS) were also positively correlated with SCZ PRS (Table [3](#Tab3){ref-type="table"}), suggesting that patients with a higher PRS tend to show more improvement in symptoms after treatment (Figure [S9](#MOESM1){ref-type="media"}) and that those with lower PRS have increased depressive symptoms. It is well known that some patients may have an increase in depressive symptoms once positive symptoms remit, being recognised as a clinical disorder (ICD F20.4 = post-SCZ depression). However, no study, to our knowledge has yet evaluated the relation between PRS and post-SCZ depression. Lastly, it is important to note that although we detected differences in these two symptom dimensions, we do not observe an association between total PANSS improvement (ΔPANSS total) and PRS SCZ. Taken together, these results suggest that FEP patients who present with higher depressive and excitement symptoms and/or who show reduction in these dimensions after treatment with risperidone have a significantly higher genetic risk for SCZ (as estimated by PRS).

It is important to note that all previous studies of PRS and symptoms in SCZ used different study designs and, moreover, their samples were composed of patients under antipsychotic treatment. Vassos et al.^[@CR15]^ suggested that the different subgroups in theirFEP sample (specifically non-affective versus affective psychosis) have different PRS, whereas our sample included only non-affective FEP. Additionally, we did not observe overall PRS differences between our FEP subgroups. In addition, a recent study, within a large population cohort of adolescents, found an association between PRS and negative symptoms but not with depressive symptoms^[@CR16]^.

One strength of our study is that all patients were antipsychotic-naïve at the baseline and received the same treatment for approximately the same time. Our study also has several limitations, primary amongst which is that our FEP sample size is small (*N* = 60). The treatment used, risperidone, has been shown to be beneficial as an augmentation therapy in MDD patients who have a high-risk for suicide^[@CR23]^ and in patients who were treatment-refractory for MDD^[@CR24]^. However, it is a unique longitudinal sample of antipsychotic naïve FEP individuals. We will increase this sample in the future but at the moment it represents a (near) unique resource. Despite these limitations, this is the first study to explore PRS before standardized treatment initiation in the FEP as well as the change in symptoms after a sufficient time period in which to observe response to treatment.

Our results suggest that drugs and other treatments may confound our understanding of the influence of PRS on symptomatology due to their effects on specific symptoms. We expect that future studies will explore additional clinical dimensions, taking into account the response to different antipsychotics, while increasing the sample size of treatment naïve patients analysed to have more statistical power. In conclusion, we have shown that that excitement and depressive symptoms are positively associated to SCZ-PRS during FEP pre-treatment but not after risperidone treatment and that increased SCZ-PRS is associated with the risperidone induced improvement of both depressive and excitement symptoms.
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